Loading…
To amend the Child Abuse Prevention and Treatment Act with respect to infants born with and identified as being affected by substance use or withdrawal symptoms, Neonatal Abstinence Syndrome, or Fetal Alcohol Spectrum Disorder, and for other purposes.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
This bill requires states receiving grants for child abuse or neglect prevention and treatment to conduct family assessments and use a risk-based approach in addressing the needs of families with infants born with, and identified as being affected by, substance use or withdrawal symptoms, or related conditions. Further, the Children's Bureau of the Administration for Children & Families must provide guidance and technical assistance with respect to these requirements.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2025 · second_quarter · Medicare/Medicaid
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $90,000
Referred to the House Committee on Education and Labor.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Medicare/Medicaid
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
2025 · first_quarter · Medicare/Medicaid
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to reimbursement of Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs.
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
2025 · first_quarter · Medicare/Medicaid
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. H.R. 879 Medicare Patient Access and Practice Stabilization Act Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs.
Client expense: Not reported · Firm income: $90,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE